Sobre 3 señales de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Historial de señales
Browse the full record of transactions filed by Bienaime Jean Jacques. Officer active across 5 companies, notably Biomarin Pharmaceutical INC. Cumulatively, 80 reports have been published. Breakdown: 21 buys · 14 sells. Total volume traded: €3.1m. History available since 30 April 2021. The latest transaction was disclosed on 17 August 2026 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Bienaime Jean Jacques
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5000 títulos@ 9,38 US$6.7% de su flujoCommon StockSEC:0001415889-25-015478:0
Salida canónica: 1 sept 2025 (T+90)
25 de 80 declaraciones
About Bienaime Jean Jacques
Jean Jacques Bienaime is a director at Biomarin Pharmaceutical INC, Immunome Inc., INCYTE CORP, Keros Therapeutics, Inc. and Ascendis Pharma A/S. He has filed 76 forms in total, and over the sampled filings period from 2021-05-03 to 2026-06-17, the reported amounts are EUR 666429 of purchases and EUR 1971653 of sales, with option exercise as the most frequent transaction type.